Immunoreactive endothelin in urine of patients with and without diabetes mellitus

Kazuhito Totsune, Masahiko Sone, Kazuhiro Takahashi, Makoto Ohneda, Keiichi Itoi, Osamu Murakami, Takao Saito, Toraichi Mouri, Kaoru Yoshinaga

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


Immunoreactive (ir-) endothelin (ET) in urine was studied with a radioimmunoassay in patients with diabetes mellitus (DM) and non-DM diseases including endocrine disorders, primary glomerular diseases, autoimmune diseases, and hematological malignancies. Twenty-four-hour excretions (mean ± SEM) of ir-ET were 8.0 ± 0.9 pmol/day in the DM group n = 13) and 9.5 ± 1.2 pmol/day in the non-DM group (n = 51). No significant differences among DM and other disease groups were noted with respect to 24-h ir-ET excretion. Reverse-phase high-performance liquid chromatography of a normal urine extract revealed a major peak eluting later than ET-1. Gel chromatography revealed a single major peak in a smaller molecular weight (MW) region in normal urine and an additional peak in larger MW region in a urine extract from a DM patient. Urinary ir-ET consists of at least two components which may be metabolites of ET or ET precursors in plasma or peptides derived from the kidney.

Original languageEnglish
Pages (from-to)S423-S424
JournalJournal of Cardiovascular Pharmacology
Publication statusPublished - 1991


  • Diabetes mellitus
  • Endothelin
  • Gel chromatography
  • High-performance liquid chromatography
  • Radioimmunoassay
  • Urine


Dive into the research topics of 'Immunoreactive endothelin in urine of patients with and without diabetes mellitus'. Together they form a unique fingerprint.

Cite this